nTMS for Brain Metastasis Planning

Palo Alto (17 mi)

Caroline Chung | MD Anderson Cancer Center

Overseen byCaroline Chung

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Approved in 6 jurisdictions

Trial Summary

What is the purpose of this trial?This trial studies how well nTMS works in planning radiation therapy for patients with brain metastases in the motor cortex. nTMS maps brain areas that control muscles, helping doctors avoid damaging these critical areas during treatment. This could lead to safer and more effective radiation therapy. nTMS has been widely used for planning in brain tumor surgeries to map important areas and improve patient outcomes.

Eligibility Criteria

This trial is for adults with brain metastases in the motor cortex who've had stereotactic radiosurgery (SRS) 3-18 months prior. Participants must be able to undergo nTMS and EMG, have used MRI for SRS planning, and complete questionnaires in English. Excluded are those with significant cognitive/psychiatric issues or poor physical status that prevents participation.

Inclusion Criteria

I have brain cancer near the motor cortex and had radiation therapy 3-18 months ago.

I can complete health questionnaires in English.

Exclusion Criteria

I can complete physical exams and answer questions without cognitive or psychiatric issues.

Treatment Details

The study tests how well nTMS aids in planning stereotactic radiosurgery for patients with brain tumors affecting muscle control. It aims to map out areas of the brain responsible for movement to determine safe radiation levels without harming these critical regions.

1Treatment groups

Experimental Treatment

Group I: Diagnostic (nTMS, sensory testing)Experimental Treatment4 Interventions

Patients undergo nTMS over 1 hour. Patients also perform 4 tasks that test grip and pinch strength, and the ability to use and feel with their hands for 1 hour.

Stereotactic Radiosurgery is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

🇪🇺 Approved in European Union as Stereotactic Radiosurgery for: